×
返回 Agenda
Session 1: Data Privacy – GDPR in Pharmacovigilance: Impact and Management of Data
Session Chair(s)
Gaby L. Danan, MD, PhD
Pharmacovigilance Expert
GLD, France
The aim of this session is to cover the key questions, examples on how has/is GDPR affecting pharmacovigilance. Incorporating different perspectives from industry and authorities, the 1st session of this interactive workshop will present what are the challenges and advantages when it comes to GDPR application in PV and what are the Non-EEA countries requirements vs. EAA harmonization.
Speaker(s)
Case Studies on how GDPR has/is Affecting Pharmacovigilance
Jean Kilgour-Christie, BSN, MSc
Sandoz International GmbH, Germany
Deputy EU QPPV Head, UK QPPV
Naveen Yelkur
Bristol-Myers Squibb, United Kingdom
Business Operations Executive
Non-EEA Countries Requirements vs. EAA Harmonization
Doris Irene Stenver, MD, MPA
Unique Advice, Denmark
Independent Pharmacovigilance Adviser
Panel discussion with Q&A
Gaby L. Danan, MD, PhD
GLD, France
Pharmacovigilance Expert